This website serves as an information platform. Thus we are pleased to provide studies and documents of interest from other institutions in this field. For the newsletter of the Pharmacoeconomic Department see https://ppri.goeg.at/news.
2023
Rejon-Parrilla JC, Espin J, Garner S, Kniazkov S and Epstein D (2023): Pricing and reimbursement mechanisms for advanced therapy medicinal products in 20 countries. Front. Pharmacol. 14:1199500. doi: 10.3389/fphar.2023.1199500
Salcher‐Konrad M, Fischer S, Knoll V, Vogler S (2023): Leistungsspektrum der öffentlichen Apotheken in Österreich – Bestandsaufnahme und Analyse (in German, title in English: Review and analysis of services provided by community pharmacies in Austria). Factsheet. Gesundheit Österreich, Vienna.
Vogler S, Salcher‐Konrad M, Knoll V (2023): Leistungsspektrum der öffentlichen Apotheken – internationaler Vergleich (in German, title in English: Services provided by community pharmacies - International comparison). Factsheet. Gesundheit Österreich, Vienna.
Schneider P, Salcher‐Konrad M: Preisanalyse oraler Kombinationspräparate zur Behandlung von Diabetes. Studienprotokoll (Price analysis of oral combination products for the treatment of diabetes. Study protocol). Vienna: Gesundheit Österreich GmbH 2023
2021
Schneider P, Fischer S, Heindl B: Internationale Preisanalyse von Medikamenten im patentabgelaufenen Markt - Studienprotokoll (International price analysis of off-patent medicines - study protocol). Vienna: Gesundheit Österreich GmbH 2021
National Policy Options for New AMR Health Technologies, Policy Brief #01: March 2021. Global AMR R&D Hub, 2021
2020
WHO guideline on country pharmaceutical pricing policies, second edition. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO. Further background information available on the WHO website here.
Colbert A, Rintoul A, Simão M, Hill S, Swaminathan S.: Can affordability and innovation coexist for medicines? BMJ 2020; 368 :l7058
Moon S, Mariat S, Kamae I, Pedersen H.: Defining the concept of fair pricing for medicines. BMJ 2020; 368 :l4726
Morgan S G, Bathula H S, Moon S.: Pricing of pharmaceuticals is becoming a major challenge for health systems. BMJ 2020; 368 :l4627
Suleman F, Low M, Moon S, Morgan S G.: New business models for research and development with affordability requirements are needed to achieve fair pricing of medicines. BMJ 2020; 368 :l4408
Cernuschi T, Gilchrist S, Hajizada A, Malhame M, Mariat S, Widmyer G et al.: Price transparency is a step towards sustainable access in middle income countries. BMJ 2020; 368 :l5375
2019
WHO: Evaluation of the Affordable Medicines Programme in Ukraine. WHO Regional Office for Europe, Copenhagen, 2019
2018
Sarnola K, Ahonen R, Martikainen J, Timonen J.: Policies and availability of orphan medicines in outpatient care in 24 European countries. In: European Journal of Clinical Pharmacology, 2018
Panteli D, Edwards S.: Policy Brief: Ensuring access to medicines: How to stimulate Innovation to meet patients’ needs?. European Observatory on Health Systems and Policies of the WHO Regional Office for Europe, 2018
WHO: Pricing of cancer medicines and its impacts. World Health Organization, Geneva, 2018.
2017
Wild C, Zechmeister-Koss I, Vogler S.: Risk-sharing Schemes und weitere Managed-Entry Agreements: Sind vertrauliche Abkommen zielführend oder kontraproduktiv? . [Title translated in English: Risk-sharing schemes and further managed entry Agreements: are confidential agreements fulfilling their target or are they counterproductive?], In: Ludwig Boltzmann Institut Health Technology Assessment, Newsletter Februar 2017: Nr. 154 , 2017, Vienna
OECD: Tackling Wasteful Spending on Health. 2017
OECD: New Health Technologies: Managing Access, Value and Sustainability . 2017
Aaltonen K.: Affordability of medicines from the pharmaceutical system perspective. Comparative analysis of Finland and New Zealand. In: Studies in Social Security and Health, 2017, Helsinki
WHO Regional Office for Europe: Health technologies and pharmaceuticals programme. Annual report 2017. Copenhagen, 2017
2016
WHO Regional Office for Europe: Challenges and opportunities in improving access to medicines through efficient public procurement in the WHO European Region. 2016, Copenhagen
Wirtz V, Hogerzeil H, Gray A, Bigdeli M, de Joncheere C, Ewen M and others: Essential medicines for universal health coverage. In: The Lancet, Vol. 389, No. 10067: , 2016
2015
WHO Regional Office for Europe: Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research. 2015
2013
Paris V, Belloni A.: Value in Pharmaceutical Pricing. In: OECD Health Working Papers 2013, No. 63: , 2013
Bouvy J, Vogler S: Priority Medicine Report. Background Paper 8.3. Pricing and Reimbursement Policies: Impacts on Innovation. In: WHO 2013, 2013
Kaplan W, Wirtz V, Mantel Teuwisse A, Stolk P, Laing R.: Priority medicines for Europe and the world - 2013 update. In: WHO 2013, 2013
Ferrario A, Kanavos P.: Managed entry agreements for pharmaceuticals: The European experience. In: The London School of Economics and Political Science 2013, 2013
Aricks F, Bucics A, Habl C.: Process on Corporate Social Responsibility in the Field of Pharmaceuticals; Platform on Access to Medicines in Europe; Final Report of the Working Group on Mechanism of Coordinated Access to Orphan Medicinal Products. In: MoCA-OMP 2013, 2013, Brussels
2012
Carone G, Schwierz C, Xavier A.: Cost-containment policies in public pharmaceutical spending in the EU. Commissioned by the European Commission, Directorate-General for Economic and Financial Affairs (Ed.), In: Brussels 2012 Economic Papers 461, 2012, Brussels
2011
Vogler S, Habl C, Leopold C, Morak S, Zimmermann N.: Pharmaceutical Health Information (PHIS) Final Technical Report. Pharmaceutical Health Information System; Written by ÖBIG, commissioned by the Executive Agency for Health and Consumers and the Austrian Federal Ministry of Health, In: Utrecht WHO Collaborating Centre for Pharmacoepidemiology and Pharmaceutical Policy 2011, 2011
Hoebert J, Mantel-Teuwisse A.: Pharmaceutical Health Information (PHIS) Evaluation Report. Complied in the framework of the Pharmaceutical Health Information System Project, In: Utrecht WHO Collaborating Centre for Pharmacoepidemiology and Pharmaceutical Policy 2011, 2011
Vogler S, Morak S.: Pharmaceutical Health Information (PHIS) Evaluation Report: Technical Interim Report. Pharmaceutical Health Information System; Written by ÖBIG, commissioned by the Executive Agency for Health and Consumers and the Austrian Federal Ministry of Health, 2011
Executive Agency of Health and Consumers (EAHC): EU Health Programme: working together to improve public health in Europe – A selection of Public Health Projects with an important impact for EU Member States”. In collaboration with the Health Programme’s National Focal Points (NFP) and the Directorate General for Health and Consumers (DG SANCO) , 2011
Kanavos P, Schurer W, Vogler S.: The Pharmaceutical Distribution Chain in the European Union: Structure and Impact on Pharmaceutical Prices. London School of Economics, Gesundheit Österreich GmbH; Commissioned by the European Commission, Directorate-General Enterprise, 2011
Kanavos P, Nicod E, Espin J, an den Aardweg S. : Short- and Long-Term Effects of Value-Based Pricing vs. External Price Referencing. London School of Economics, Andalusian School of Public Health; Commissioned by the European Commission, Directorate-General Enterprise, 2011
Espín J, Rovira J, García L.: Experiences and Impact of European Risk-Sharing Schemes Focusing on Oncology Medicines. Andalusian School of Public Health ; Commissioned by the European Commission, Directorate-General Enterprise, 2011
2009
Kanavos P, Seeley L, Vandoros S, Aardweg S. : Tender systems for outpatient pharmaceuticals in the European Union: Evidence from the Netherlands, Germany and Belgium. London School of Economics; Commissioned by the European Commission, Directorate-General Enterprise, 2009
2008
OECD Health Policy Studies: Pharmaceutical Pricing Policies in a Global Market. Commissioned by the Organisation for Economic Co-operation and Development, 2008
2007
Espín J, Rovira J.: Analysis of differences and commonalities in pricing and reimbursement systems in Europe. Andalusian School of Public Health; Commissioned by the European Commission, Directorate-General Enterprise, 2007
2006
Vogler S, Habl C.: Pharmaceutical Pricing and Reimbursement Information (PPRI): Technical Interim Report. Commissioned by the European Commission, Directorate-General Health and Consumer Protection and Austrian Federal Ministry of Health, Family and Youth, 2006